Use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease

episode

Neurology® Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Trump hosts President Xi at state banquet 31 min · 25 Sep 2026 · Global News Podcast

TNA Reaction: Sawyer & Shaw Arrive 18 min · 25 Sep 2026 · Busted Open

12AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

New Music Friday: The best albums out Sept. 25 44 min · 25 Sep 2026 · NPR Music

r/Bestof My Sister is a Nutjob 18 min · 25 Sep 2026 · rSlash

The Resurrection of Christ 26 min · 25 Sep 2026 · Renewing Your Mind

Report any issue

Source

Recorded08 Jul 2019

Publisherneurology.libsyn.com ↗

Handlerec:5447920

Show notes

In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration's authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in